Institutional investors purchased a net $1.1 million shares of TROV during the quarter ended December 2014. This may signal that the smart money is gaining interest in this company as the 21.08% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BRIDGER MANAGEMENT LLC Bought 707.7 Thousand shares of Trovagene Inc